Syringes was Retractable Technologies’s largest product and service line in fiscal 2025, bringing in $24.91M of $38.27M (65%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Syringes | $86.74M | $34.16M | $22.63M | $24.91M | ||||||
| Easypoint Needles | $4.67M | $7.25M | $8.95M | $11.94M | ||||||
| Easy Point Needles | — | — | — | — | ||||||
| Blood Collection Products | $2.95M | $1.93M | $1.43M | $1.37M | ||||||
| Licensing Fees | — | $778.00K | $189.00K | — | ||||||
| Other Products | $451.95K | $266.27K | $45.85K | $43.63K | ||||||
| Total | $94.82M | $44.37M | $33.24M | $38.27M |
Retractable Technologies brought in $38.27M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Retractable Technologies regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $33.24M. Syringes was the largest at $24.91M (65.1%), ahead of Easypoint Needles at $11.94M (31.2%) and Blood Collection Products at $1.37M (3.6%). The remaining line, Other Products, brought in $43.63K.
Compared with fiscal 2024, Easypoint Needles grew fastest, up 33.5% to $11.94M, while Blood Collection Products fell the most, down 3.9% to $1.37M. From fiscal 2022 to 2025, combined revenue from these lines fell from $94.82M to $38.27M, a compound annual decline of 26.1%. Syringes' share of the total fell from 91.5% to 65.1%.
Retractable Technologies stopped reporting Licensing Fees as a separate line after fiscal 2024, when it brought in $189.00K.
U.S. Sales was Retractable Technologies’s largest revenue line in fiscal 2025, bringing in $32.24M of $38.27M (84%).
| Customer | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| U.S. Sales (Excluding U.S. Government) | $36.49M | $34.60M | — | — |
| U.S. Sales | — | — | $29.37M | $32.24M |
| Sales To U.S. Government | $15.73M | — | — | — |
| North & South America Sales (Excluding U.S.) | $29.13M | $6.09M | $1.96M | $5.06M |
| Other International Sales | $13.47M | $2.91M | $1.71M | $968.61K |
| Total | $94.82M | $43.60M | $33.05M | $38.27M |
Retractable Technologies brought in $38.27M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 15.8% from $33.05M in fiscal 2024. U.S. Sales was the largest at $32.24M (84.2%), ahead of North & South America Sales (Excluding U.S.) at $5.06M (13.2%) and Other International Sales at $968.61K (2.5%).
Compared with fiscal 2024, North & South America Sales (Excluding U.S.) grew fastest, up 158.1% to $5.06M, while Other International Sales fell the most, down 43.5% to $968.61K.
Retractable Technologies began breaking out U.S. Sales in fiscal 2024, when it brought in $29.37M. Retractable Technologies stopped reporting U.S. Sales (Excluding U.S. Government) ($34.60M in fiscal 2023) and Sales To U.S. Government ($15.73M in fiscal 2022) as separate revenue lines.
U.S. Sales was Retractable Technologies’s largest region in fiscal 2019, bringing in $31.90M of $41.80M (76%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| U.S. Sales | — | — | — | $31.90M | ||||||
| U.S | — | $27.02M | $28.65M | — | ||||||
| United States | $26.31M | — | — | — | ||||||
| Us | — | — | — | — | ||||||
| North & South America (Excluding U.S) | — | — | — | $8.25M | ||||||
| Segment Geographical Groups Of Countries Group One | — | — | — | — | ||||||
| North & South America Sales (Excluding U.S.) | $2.74M | $6.38M | $3.60M | — | ||||||
| North & South America Excluding United States | — | — | — | — | ||||||
| Other International Sales | $776.87K | $1.10M | $1.03M | $1.65M | ||||||
| Other International | — | — | — | — | ||||||
| Segment Geographical Groups Of Countries Group Two | — | — | — | — | ||||||
| Total | $29.83M | $34.49M | $33.27M | $41.80M |
Retractable Technologies brought in $41.80M from its three regions in fiscal 2019, the year ended December 31, 2019. Retractable Technologies regrouped these regions after fiscal 2018, so the total does not compare directly with that year's $33.27M. U.S. Sales was the largest at $31.90M (76.3%), ahead of North & South America (Excluding U.S) at $8.25M (19.7%) and Other International Sales at $1.65M (3.9%).
Retractable Technologies began breaking out U.S. Sales in fiscal 2019 and North & South America (Excluding U.S) in fiscal 2019. Retractable Technologies stopped reporting U.S ($28.65M in fiscal 2018), United States ($26.31M in fiscal 2016) and North & South America Sales (Excluding U.S.) ($3.60M in fiscal 2018) as separate regions.
Retractable Technologies (RVP) reports its revenue by product and service, by customer and by geography. In fiscal 2025, Syringes was its largest product and service line, bringing in $24.91M (65.1% of the total), followed by Easypoint Needles at $11.94M (31.2%).
Syringes was Retractable Technologies' largest product and service line in fiscal 2025, bringing in $24.91M, or 65.1% of the $38.27M total across its four product and service lines.
U.S. Sales was Retractable Technologies' largest revenue line in fiscal 2025, bringing in $32.24M, or 84.2% of the $38.27M total across its three revenue lines.
U.S. Sales was Retractable Technologies' largest region in fiscal 2019, bringing in $31.90M, or 76.3% of the $41.80M total across its three regions.
Among Retractable Technologies' revenue lines that make up at least 2% of revenue, North & South America Sales (Excluding U.S.) grew fastest in fiscal 2025, up 158.1% from $1.96M to $5.06M.
Every figure comes from Retractable Technologies' annual financial filings, as reported. Each line keeps the name Retractable Technologies gives it, and years follow its fiscal calendar.
Retractable Technologies' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.